Latest Content

Steering the Treatment of Gynecologic Cancers With Biomarkers

September 13th 2024, 1:00pm

By Darlene Dobkowski, MA

Article

Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.

FDA Approves Subcutaneous Tecentriq Formulation

September 12th 2024, 11:28pm

By Darlene Dobkowski, MA

Article

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

Darzalex Regimen Boosts Rates of MRD Negativity in Newly Diagnosed, Transplant-Eligible Myeloma

September 12th 2024, 9:00pm

By Chris Ryan

Article

A Darzalex-based regimen improved MRD negativity rates compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.

Why Biomarkers Are a ‘Double-Edged Sword’ for Patients and Providers

September 12th 2024, 7:00pm

By Alex Biese

Article

As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the questions they raise.

How I Found Out About My Breast Cancer Diagnosis

September 12th 2024, 5:00pm

By Natasha Carlson

Article

Receiving a diagnosis of breast cancer was one of the more traumatic moments I’ve experienced, but the way I found out added to that.

Choices About Cancer Treatment During a Tumultuous Time

September 12th 2024, 3:00pm

By Mike Hennessy Jr.

Article

In this Fall issue of CURE, we focus on AYAs with cancer, latest treatments in small cell lung cancer, preparing for a virtual visit and answering common questions about breast cancer.

Frontline Ivonescimab May Further Reduce Progression or Death Risk Versus Keytruda in NSCLC Subset

September 12th 2024, 1:00pm

By Caroline Seymour

Article

Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ivonescimab versus Keytruda.

Opdivo Before and After Surgery Lowers Risk of Recurrence or Death by 40% in NSCLC

September 11th 2024, 9:00pm

By Ashley Chan

Article

Patients with non-small cell lung cancer saw a reduction in their risk of recurrence or death after surgery when treated with pre- and postsurgical Opdivo.

Navigating Clinical Trials in Gynecologic Cancers

September 11th 2024, 7:00pm

By Spencer Feldman

Article

Patients can benefit from clinical trials in gynecologic cancers, and knowing that they can advocate for themselves for potential consideration for study enrollment.

Dealing With the Uncertainty of Cancer

September 11th 2024, 5:00pm

By Ronald Chin

Article

Since my diagnosis with multiple myeloma, I try to keep inspired to keep moving forward despite the challenges.

A New Era in Small Cell Lung Cancer Treatment

September 11th 2024, 3:00pm

By Debu Tripathy

Article

Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.

Adcetris Plus Revlimid and Rituxan Continues to Improve Relapsed/Refractory Diffuse Large B-Cell Lymphoma Results

September 11th 2024, 1:00pm

By Kristi Rosa

Article

Adcetris plus Revlimid/Rituxan significantly improved outcomes versus Revlimid/Rituxan alone in relapsed/refractory lymphoma.

First-Line Rybrevant Plus Lazcluze Shows Trend Toward Overall Survival in EGFR-Positive NSCLC

September 10th 2024, 9:00pm

By Ashley Chan

Article

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer.

‘Never Give Up’: Treatment Breakthroughs Arrive for SCLC

September 10th 2024, 7:00pm

By Alex Biese

Article

With pivotal trial results and an approval from the FDA, the landscape is changing for patients with small cell lung cancer.

Yes, You Can Donate Many Unused Cancer Drugs

September 10th 2024, 5:00pm

By Martha Carlson

Article

A patient with metastatic breast cancer confronts financial toxicity and finds a little glimmer of hope through donating cancer drugs.